Appendix A. Skin biopsy of the left calf taken during flare-up shows a slight epidermic atrophy with a lymphocytary infiltrate. Moreover, a mixed infiltrate with perivascular lymphocytes and abundant dermic eosinophils can be observed. In the center of the biopsy a subcorneal pustule constituted by polymorphonuclears, eosinophils and neutrophils can be seen (Hematoxilin-Eosin stain; original magnification x10, x40 respectively).

No abstract

Intradermal tests. Palabras clave: Remdesivir. COVID-19. Hipersensibilidad no inmediata. Pruebas epicutáneas. Pruebas cutáneas en intradermorreacción. Remdesivir (GS-5734) is a prodrug of an adenosine nucleotide analogue with a potent antiviral activity against filoviruses, paramyxoviruses, pneumoviruses and coronaviruses. After being outperformed by monoclonal antibodies for the treatment of Ebola virus during the 2014-2016 Ebola outbreak in West Africa, it remained unused until the novel coronavirus disease 2019 (COVID-19) pandemic broke out. Phase III trials of remdesivir in COVID-19 were initiated on February 2020 and received an emergency use authorization by FDA [1,2]. Since its use for the treatment of COVID-19 began, adverse events were reported, such as increased hepatic enzymes, diarrhea, and skin reactions, among others [3]. We report a case of maculopapular exanthema induced by remdesivir confirmed by patch tests (PTs) and intradermal skin tests (IDTs).A 75-year-old woman with a medical history of asthma and obstructive sleep apnea-hypopnea syndrome was admitted to the hospital due to double pneumonia and respiratory failure caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection. Because of a lack of response to high-flow oxygen, continuous positive airway pressure and intravenous bolus of corticosteroids, remdesivir treatment